A detailed history of Tectonic Advisors LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Tectonic Advisors LLC holds 712 shares of REGN stock, worth $499,717. This represents 0.05% of its overall portfolio holdings.

Number of Shares
712
Previous 784 9.18%
Holding current value
$499,717
Previous $824,000 9.22%
% of portfolio
0.05%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$1024.09 - $1201.76 $73,734 - $86,526
-72 Reduced 9.18%
712 $748,000
Q2 2024

Aug 02, 2024

BUY
$883.2 - $1071.19 $29,145 - $35,349
33 Added 4.39%
784 $824,000
Q1 2024

May 07, 2024

SELL
$902.69 - $993.35 $28,886 - $31,787
-32 Reduced 4.09%
751 $722,000
Q4 2023

Jan 17, 2024

BUY
$775.18 - $881.7 $10,852 - $12,343
14 Added 1.82%
783 $687,000
Q3 2023

Oct 23, 2023

BUY
$692.45 - $844.37 $24,235 - $29,552
35 Added 4.77%
769 $632,000
Q2 2023

Jul 13, 2023

BUY
$700.03 - $830.35 $32,201 - $38,196
46 Added 6.69%
734 $527,000
Q1 2023

Apr 25, 2023

BUY
$680.49 - $826.97 $107,517 - $130,661
158 Added 29.81%
688 $565,000
Q4 2022

Feb 14, 2023

SELL
$705.89 - $766.39 $6,353 - $6,897
-9 Reduced 1.67%
530 $382,000
Q3 2022

Nov 08, 2022

BUY
$573.97 - $724.32 $23,532 - $29,697
41 Added 8.23%
539 $371,000
Q2 2022

Aug 11, 2022

BUY
$548.35 - $738.84 $22,482 - $30,292
41 Added 8.97%
498 $294,000
Q1 2022

May 09, 2022

BUY
$595.12 - $698.43 $41,063 - $48,191
69 Added 17.78%
457 $319,000
Q4 2021

Feb 02, 2022

BUY
$543.48 - $670.97 $210,870 - $260,336
388 New
388 $245,000
Q1 2021

May 18, 2021

SELL
$446.73 - $548.2 $506,145 - $621,110
-1,133 Closed
0 $0
Q4 2020

May 17, 2021

BUY
$478.3 - $607.98 $541,913 - $688,841
1,133 New
1,133 $547,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Tectonic Advisors LLC Portfolio

Follow Tectonic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tectonic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tectonic Advisors LLC with notifications on news.